Northwest Biotherapeutics has developed an autologous (the body's own) “DCVax®” immunotherapy for various types of cancer. In the USA, the company is already conducting clinical trials for the treatment of glioblastomas and other types of cancer. Such immunotherapies for cancer are beginning to succeed after many decades of research and development. DCVax® is one of the leading technologies at the forefront of this new approach to cancer treatment.
In order to make this DCVax® therapy also available to patients in Europe, the company has now entered cooperation with the Fraunhofer IZI. The initial phase of this cooperation comprises adapting the production processes to European regulations and standards, implementing them in the Fraunhofer IZI's facilities and comprehensive quality management system and obtaining the required official authorizations. Later on, the clinical trial products are supposed to be provided by the Fraunhofer IZI.
The current methods for the treatment of glioblastomas are limited and do not yield the desired success: Patients typically only live for about 14 months after diagnosis. Treatment options are restricted to surgical intervention, irradiation and chemotherapy, which are all associated with considerable risks and side effects. The autologous immunotherapy DCVax® Brain is now expected to provide treatment with improved therapeutic success (potentially adding years of survival) and attenuated side effects.
The autologous immunotherapy DCVax® Brain is based on dendritic cells, which play a key role in the regulation of the immune system. As tumor tissues develop from the body's own cells, the immune system often does not recognize them as foreign tissues and therefore does not attack them. In the DCVax® method, the dendritic cells are primed to specific antigens (bio-markers) that exist on the tumor cells. Consequently, the modified cells stimulate the T cells, the B cells and antibodies, and other agents of the immune system to combat the corresponding tumor cells.
The initial step is the isolation of immune cells (monocytes) from the patient's blood, followed by their cultivation and maturation into dendritic cells in the laboratory. In this process, the cells are co-incubated with fragments of the patient's tumor and primed to the corresponding specific tumor antigens. Several injections of the DCVax® dendritic cells thus generated will stimulate the patient's immune system to combat all tumor cells that bear the corresponding tumor antigens on their surface. This technology offers an important new approach to treating cancer, and is expected to be applicable to all cancers.contact
The Fraunhofer Institute for Cell Therapy and Immunology IZI is member of the Fraunhofer Group for Life Sciences. Its objective being to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute’s core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept the tissues without any difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during process and product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. The Institute works especially closely with hospital institutions, performing quality tests and clinical studies on their behalf. Additionally it also provides assistance in obtaining manufacturing licenses and certifications.Fraunhofer Institute for Cell Therapy and Immunology
GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University
Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center
Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.
Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.
Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
23.04.2018 | Physics and Astronomy
23.04.2018 | Physics and Astronomy
23.04.2018 | Trade Fair News